The methionine-homocysteine cycle and its effects on cognitive diseases

Alternative Medicine Review

Volumn 8, Issue 1, 2003, Pages 7-19

  Miller, Alan L ^a  

^a Thorne Research Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; DNA; FOLIC ACID; HOMOCYSTEINE; METHIONINE; METHYL GROUP; PROTEIN; PYRIDOXINE; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE; SULFUR AMINO ACID;

AGING; ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; APOPTOSIS; BRAIN PROTECTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DAMAGE; COGNITION; COGNITIVE DEFECT; FOLIC ACID BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; MEMORY DISORDER; METABOLITE; METHYLATION; MULTIINFARCT DEMENTIA; NUTRITION; REVIEW; RISK FACTOR; VITAMIN BLOOD LEVEL;

ALZHEIMER DISEASE; CARDIOVASCULAR DISEASES; COGNITION DISORDERS; DEMENTIA, VASCULAR; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MEMORY DISORDERS; METHIONINE; METHIONINE ADENOSYLTRANSFERASE; VITAMIN B 12; VITAMIN B 12 DEFICIENCY; VITAMIN B 6;

EID: 0037297716     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Miller AL, Kelly GS. Homocysteine metabolism: nutritional modulation and impact on health and disease. Altern Med Rev 1997;2:234-254.
2. Urnov FD. Methylation and the genome: the power of a small amendment. J Nutr 2002;132:2450S-2456S.
3. Zhu BT. On the mechanism of homocysteine pathophysiology and pathogenesis: a unifying hypothesis. Histol Histopathol 2002;17:1283-1291.
4. Bautista LE, Arenas IA, Penuela A, Martinez LX. Total plasma homocysteine level and risk of cardiovascular disease: a meta-analysis of prospective cohort studies. J Clin Epidemiol 2002;55:882-887.
5. No authors listed. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-2022.
6. Hopkins P, Wu L, Wu J, et al. Higher plasma homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1995;15:1314-1320.
7. Loehrer F, Angst C, Haefeli W, et al. Low whole-blood S-adenosylmethionine and correlation between 5-methyltetrahydrofolate and homocysteine in coronary artery disease. Arterioscler Thromb Vasc Biol 1996;16:727-733.
8. Boushey C, Beresford S, Omenn G, Motulsky A. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-1057.
9. Robinson K, Mayer E, Miller D, et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995;92:2825-2830.
10. Nikfardjam M, Graf S, Hornykewycz S, et al. Homocysteine plasma levels in young patients with coronary artery disease. Relation to history of acute myocardial infarction and anatomical extent of disease. Thromb Res 2001;103:S35-S39.
11. Landgren F, Israelsson B, Lindgren A, et al. Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J Int Med 1995;237:381-388.
12. Chasan-Taber L, Selhub J, Rosenberg I, et al. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 1996;15:136-143.
13. Knekt P, Alfthan G, Aromaa A, et al. Homocysteine and major coronary events: a prospective population study amongst women. J Intern Med 2001;249:461-465.
14. Whincup PH, Refsum H, Perry IJ, et al. Serum total homocysteine and coronary heart disease: prospective study in middle aged men. Heart 1999;82:448-454.
15. Bots ML, Launer LJ, Lindemans J, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med 1999;159:38-44.
16. Brattstrom L, Lindgren A, Israelsson B, et al. Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest 1992;22:214-221.
17. Perry IJ, Refsum H, Morris RW, et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-1398.
18. Hultberg B, Andersson A, Lindgren A. Marginal folate deficiency as a possible cause of hyperhomocystinaemia in stroke patients. Eur J Clin Chem Clin Biochem 1997;35:25-28.
19. Molgaard J, Malinow MR, Lassvik C, et al. Hyperhomocyst(e)inaemia: an independent risk factor for intermittent claudication. J Intern Med 1992;231:273-279.
20. Cheng SW, Ting AC, Wong J. Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease. Ann Vasc Surg 1997;11:217-223.
21. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-762
22. Beaumont V, Malinow MR, Sexton G, et al. Hyperhomocyst(e)inemia, anti-estrogen antibodies and other risk factors for thrombosis in women on oral contraceptives. Atherosclerosis 1992;94:147-152.
23. No authors listed. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. BMJ 1998;316:894-898.
24. Schnyder G, Roffi M, Flammer Y, et al. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA 2002;288:973-979.
25. Yap S, Boers GH, Wilcken B, et al. Vascular outcome in patients with homocysteinuria due to cystathione beta-synthase deficiency treated chronically: a multicenter observational study. Arterioscler Thromb Vasc Biol 2001;21:2080-2085.
26. Wouters MGAJ, Moorrees MTEC, Van der Mooren MJ, et al. Plasma homocysteine and menopausal status. Eur J Clin Invest 1995;25:801-805.
27. Brattstrom L, Lindgren A, Isrealsson B, et al. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med 1994;236:633-641.
28. Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile - the Hordaland homocysteine study. JAMA 1995;274:1526-1533.
29. Nygard O, Refsum H, Ueland PM, et al. Coffee consumption and plasma total homocysteine: The Hordaland Homocysteine Study. Am J Clin Nutr 1997;65:136-143.
30. Cravo ML, Gloria LM, Selhub J, et al. Hyperhomocysteinemia in chronic alcoholism: correlation with folate, vitamin B-12, and vitamin B-6 status. Am J Clin Nutr 1996;63:220-224.
31. Hultberg B, Berglund M, Andersson A, Frank A. Elevated plasma homocysteine in alcoholics. Alcohol Clin Exp Res 1993; 17:687-689.
32. Flippo TS, Holder WD Jr. Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency. Arch Surg 1993;128:1391-1395.
33. Quinn K, Basu TK. Folate and vitamin B12 status of the elderly. Eur J Clin Nutr 1996;50:340-342.
34. Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 1988;318:1720-1728.
35. Lindenbaum J, Rosenberg IH, Wilson PW, et al. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr 1994;60:2-11.
36. Joosten E, van den Berg A, Riezler R, et al. Metabolic evidence that deficiencies of vitamin B-12 (cobalamin), folate, and vitamin B-6 occur commonly in elderly people. Am J Clin Nutr 1993;58:468-476.
37. Pennypacker LC, Allen RH, Kelly JP, et al. High prevalence of cobalamin deficiency in elderly outpatients. J Am Geriatr Soc 1992;40:1197-1204.
38. Metz J, Bell AH, Flicker L, et al. The significance of subnormal serum vitamin B12 concentration in older people: a case control study. J Am Geriatr Soc 1996;44:1355-1361.
39. Nilsson K, Gustafson L, Hultberg B. The plasma homocysteine concentration is better than that of serum methylmalonic acid as a marker for sociopsychological performance in a psychogeriatric population. Clin Chem 2000;46:691-696.
40. Morris MS, Jacques PF, Rosenberg IH, Selhub J. Hyperhomocysteinemia associated with poor recall in the third National Health and Nutrition Examination Survey. Am J Clin Nutr 2001;73:927-933.
41. Riggs KM, Spiro A 3rd, Tucker K, Rush D. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr 1996;63:306-314.
42. Duthie SJ, Whalley LJ, Collins AR, et al. Homocysteine, B vitamin status, and cognitive function in the elderly. Am J Clin Nutr 2002;75:908-913.
43. Stewart R, Asonganyi B, Sherwood R. Plasma homocysteine and cognitive impairment in an older British African-Caribbean population. J Am Geriatr Soc 2002;50:1227-1232.
44. McCaddon A, Hudson P, Davies G, et al. Homocysteine and cognitive decline in healthy elderly. Dement Geriatr Cogn Disord 2001;12:309-313.
45. Boers GH, Smals AG, Trijbels FJ, et al. Heterozygosity for homocysteinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985;313:709-715.
46. Pasini FL, Frigerio C, Petri S, diPerri T. Plasma homocysteine in ischemic stroke. Stroke 1995;6:795-800.
47. McIlroy SP, Dynan KB, Lawson JT, et al. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke 2002;33:2351-2356.
48. Leblhuber F, Walli J. Homocysteine and B vitamins in dementia. Am J Clin Nutr 2001;73:127-134. [letter]
49. Bertsch T, Mielke O, Holy S, et al. Homocysteine in cerebrovascular disease: an independent risk factor for subcortical vascular encephalopathy. Clin Chem Lab Med 2001;39:721-724.
50. Lehmann M, Gottfries CG, Regland B. Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement Geriatr Cogn Disor 1999;10:12-20.
51. Evers S, Koch H, Grotemeyer K, et al. Features, symptoms, and neurophysiological findings in stroke associated with hyperhomocysteinemia. Arch Neurol 1997;54:1276-1282.
52. Kalmijn S, Launer LL, Lindemans J, et al. Total homocysteine and cognitive decline in a community-based sample of elderly subjects. Am J Epidemiol 1999;150:283-289.
53. Nilsson K, Gustafson L, Hultberg B. Relationship between plasma homocysteine and Alzheimer's disease. Dement Geriatr Cogn Disord 2002;14:7-12.
54. Clarke R, Smith AD, Jobst KA, et al. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998;55:1449-1455.
55. McCaddon A, Davies G, Hudson P, et al. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998;13:235-239.
56. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-483.
57. Joosten E, Lesaffre E, Riezler R, et al. Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? J Gerontol A Biol Sci Med Sci 1997;52:M76-M79.
58. Selley ML, Close DR, Stem SE. The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol Aging 2002;23:383-388.
59. Wang HX, Wahlin A, Basun H, et al. Vitamin B(12) and folate in relation to the development of Alzheimer's disease. Neurology 2001;56:1188-1194.
60. Nilsson K, Gustafson L, Faldt R, et al. Hyperhomocysteinemia - a common finding in a psychogeriatric population. Eur J Clin Invest 1996;26:853-859.
61. Nilsson K, Gustafson L, Hultberg B. Improvement of cognitive functions after cobalamin/folate supplementation in elderly patients with dementia and elevated plasma homocysteine. Int J Geriatr Psychiatry 2001;16:609-614.
62. Snowdon DA, Tully CL, Smith CD, et al. Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun Study. Am J Clin Nutr 2000;71:993-998.
63. Nilsson K, Warkentin S, Hultberg B, et al. Treatment of cobalamin deficiency in dementia, evaluated clinically and with cerebral blood flow measurements. Aging (Milano) 2000;12:199-207.
64. Van Asselt DZ, Pasman JW, van Lier HJ, et al. Cobalamin supplementation improves cognitive and cerebral function in older, cobalamin-deficient persons. J Gerontol A Biol Sci Med Sci 2001;56:M775-M779.
65. Kwok T, Tang C, Woo J, et al. Randomized trial of the effect of supplementation on the cognitive function of older people with subnormal cobalamin levels. Int J Geriatr Psychiatry 1998;13:611-616.
66. Teunisse S, Bollen AE, van Gool WA, Walstra GJ. Dementia and suboptimal levels of vitamin B12: effects of replacement therapy on dementia. J Neurol 1996;243:522-529.
67. Carmel R, Gott PS, Waters CH, et al. The frequently low cobalamin levels in dementia usually signify treatable metabolic, neurologic and electrophysiologic abnormalities. Eur J Heamatol 1995;54:245-253.
68. Levitt AJ, Karlinsky H. Folate, vitamin B12 and cognitive impairment in patients with Alzheimer's disease. Acta Psychiatr Scand 1992;86:301-305.
69. Miller JW, Green R, Mungas DM, et al. Homocysteine, vitamin B6, and vascular disease in AD patients. Neurology 2002;58:1471-1475.
70. Bottiglieri T, Godfrey P, Flynn T, et al. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry 1990;53:1096-1098.
71. Morrison LD, Smith DD, Kish SJ. Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease. J Neurochem 1996;67:1328-1331.
72. Chambers JC, Ueland PM, Obeid OA, et al. Improved vascular endothelial function after oral B vitamins. Circulation 2000;102:2479-2483.
73. Stamler J, Osborne J, Jaraki O, et al. Adverse effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91:308-318.
74. Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000;71:621S-629S.
75. Ho PI, Ortiz D, Rogers E, Shea TB. Multiple aspects of homocysteine neurotoxicity: Glutamate excitotoxicity, kinase hyperactivation, and DNA damage. J Neurosci Res 2002;70:694-702.
76. Kruman II, Kumaravel TS, Lohani A, et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental model of Alzheimer's disease. J Neurosci 2002;22:1752-1762.
77. White AR, Huang X, Jobling MF, et al. Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's-type neurodegenerative pathways. J Neurochem 2001;76:1509-1520.
78. Ho PI, Collins SC, Dhitavat S, et al. Homocysteine potentiates amyloid beta neurotoxicity: role of oxidative stress. J Neurochem 2001;78:249-253.
79. Olney JW, Price MT, Salles KS, et al. L-homocysteic acid: an endogenous excitotoxic ligand of the NMDA receptor. Brain Res Bull 1987;19:597-602.
80. Parsons RB, Waring RH, Ramsden DB, Williams AC. In vitro effect of the cysteine metabolites homocysteic acid, homocysteine and cysteic acid upon human neuronal cell lines. Neurotoxicology 1998;19:599-604.
81. Kruman II, Culmsee C, Chan Al, et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000;20:6920-6926.
82. James SJ, Melnyk S, Pogribna M, et al. Elevation of S-adenosylhomocysteine and DNA hypomethylation: potential epigenetic mechanism for homocysteine-related pathology. J Nutr 2002;132:2361S-2366S.
83. West RL, Lee JM, Maroun LE. Hypomethylation of the amyloid precursor protein gene in the brain of an Alzheimer's disease patient. J Mol Neurosci 1995;6:141-146.
84. Rogaev EI, Lukiw WJ, Lavrushina O, et al. The upstream promoter of the beta-amyloid precursor protein gene (APP) shows differential patterns of methylation in human brain. Genomics 1994;22:340-347.